The tweet was deleted by the author.
But we saved everything 🙂.
Kura Oncology announced it will share several new abstracts at the 68th American Society of Hematology (ASH) Annual Meeting. The presentations, in collaboration with Kyowa Kirin, will include first results from clinical studies on combination treatment strategies for acute myeloid leukemia (AML).
The company is expected to introduce new clinical data, highlighting its ongoing research efforts in AML therapies. Details on the specific findings will be presented at the ASH event.
View post on X Loading...
Kura Oncology recently began enrolling patients in its FIT-001 Phase 1b trial, investigating a farnesyl transferase inhibitor combination therapy in advanced renal cell carcinoma. The company also scheduled an investor webcast to discuss the launch of Caspian Therapeutics and share KO-7246 preclinical data. These developments reflect Kura's ongoing expansion of its clinical research portfolio.